Isomorphic Labs Raises $2.1 Billion to Design Drugs with AI
Isomorphic Labs, the DeepMind drug-discovery spinout, raised $2.1 billion in a Series B led by Thrive Capital to accelerate its AI-first approach to designing therapeutics.
What Drove This Round?
AlphaFold-derived models give Isomorphic a structural-biology advantage in drug design
Pharma partnerships with Novartis and Eli Lilly validate the commercial pipeline
Capital funds expansion of compute, wet-lab capacity, and a growing scientific team
AI-native drug discovery promises to compress timelines and cut R&D costs dramatically
Thrive Capital led with deep participation from existing strategic backers
Impact Analysis
The raise is one of the largest ever for an AI biotech and signals that investors believe AI can fundamentally rewire pharmaceutical R&D. The capital lets Isomorphic move from in-silico design toward owning more of the discovery-to-clinic pipeline, fueling demand for computational biologists, ML researchers, and medicinal chemists who can work at the intersection of AI and life sciences.